Amiodarone therapy does not compromise subsequent heart transplantation
| Autor: | Michele A. Hamilton, Leslie A. Saxon, Jaime Moriguchi, Davis C. Drinkwater, Erica Brownfield, William G. Stevenson, Jon A. Kobashigawa, Hillel Laks, Catherine Chelimsky-Fallick, Lynne Warner Stevenson, Holly R. Middlekauff |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Inotrope
Cardiotonic Agents medicine.medical_treatment Amiodarone Hospitals University Postoperative Complications Heart Rate Forced Expiratory Volume Heart rate Medicine Humans Aged Retrospective Studies Heart transplantation Ejection fraction business.industry Cardiac Pacing Artificial Hemodynamics Atrial fibrillation Arrhythmias Cardiac Stroke Volume Perioperative Length of Stay Middle Aged medicine.disease Los Angeles Respiration Artificial Patient Discharge Transplantation Treatment Outcome Anesthesia Feasibility Studies Heart Transplantation Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 20(7) |
| ISSN: | 0735-1097 |
| Popis: | Objectives. The objective of this study was to determine the frequency of pulmonary complications, Feasibility of early hospital discharge and requirements for postoperative inotropic and chronotropic support in patients receiving emiodarone therapy before heart transplantation. Background. Although many patients waiting for heart transplantation will die of arrhythmias before a donor heart is found, the use of amiodarone has been limited by concern about increased complications in the perioperative period. Methods. The 29 patients receiving amiodarone at the time of heart transplantation at University of California, Los Angeles Medical Center between October 1986 and September 1990 were compared with 29 control recipients to evaluate postoperative morbidity. Patients were receiving amiodarone for recurrent ventricular tachyarrhythmias (n = 11), atrial fibrillation (n = 2) or complex ventricular ectopic activity (n = 16). The average daily dose was 360 ± 230 mg/day for an average of 11 ± 22 months before transplantation. Amiodarone and control groups had a similar ejection fraction (0.18 ± 0.07 vs. 0.20 ± 0.08), frequency of coronary disease, age and gender. There were three more status I patients in the control group. OKT3 was given to only two patients receiving amiodarone and 12 control patients at high risk for renal dysfunction. Results. Postoperatively, the duration of assisted ventilation was 21 ± 19 h after amiodarone therapy versus 26 ± 2 h in the control group (20 ± 18 h vs. 15 ± 9 h after excluding patients receiving OKT3), discharge arterial oxygen saturation was >95% in both groups. Two patients in the amiodarone group with a smoking history of >;100 pack-years developed bilateral pulmonary infiltrates of brief duration. Although patients receiving amiodarone required atrial pacing more frequently (eight vs. two patients) and had a lower heart rate at discharge (75 ± 18 vs. 86 ± 11 boats/nin), the duration of inotropic support (2.1 ± 1.5 vs. 3.5 ± 2.5 days) and of hospital stay (10 ± 3 vs. 15 ± 10 days) was not higher in the amiodarone than in the control group. The mortality rate at 30 days was similar in the two groups (6.8% vs. 3.4%, p = NS). Conclusions. Amiodarone therapy before heart transplantation may contribute to occasional pulmonary complications but does not significantly increase perioperative morbidity or mortality with the regimens used in this retrospective study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|